
Estrogen receptor alpha - Wikipedia
Estrogen receptor alpha (ERα), also known as NR3A1 (nuclear receptor subfamily 3, group A, member 1), is one of two main types of estrogen receptor, a nuclear receptor (mainly found as …
ESR1 Gene - GeneCards | ESR1 Protein | ESR1 Antibody
2024年12月25日 · ESR1 (Estrogen Receptor 1) is a Protein Coding gene. Diseases associated with ESR1 include Estrogen Resistance and Breast Cancer. Among its related pathways are …
Exploring the role of ESR1 mutations in metastatic hormone …
2025年2月7日 · This study aims to identify if ESR1 mutations generate specific T cell responses against ESR1 neoantigens in patients with HR + HER2 − BC, and to investigate if ESR1 …
ESR1 mutation as an emerging clinical biomarker in metastatic …
2021年8月15日 · In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by …
ESR1 - My Cancer Genome
ESR1 (estrogen receptor 1, also known as ER) is a gene that encodes the estrogen receptor protein. ESR1 plays a role in pathogenesis of cancers such as breast, endometrial, and …
ESR1 Mutations in Hormone Receptor Positive Breast Cancer
Estrogen receptor 1 (ESR1) mutations have emerged as a critical player in the progression and treatment resistance of breast cancer, particularly in metastatic hormone receptor-positive cases.
ESR1 mutations are frequent in newly diagnosed metastatic and …
2020年2月3日 · ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10–50%) in metastatic, endocrine therapy-resistant cancers and are associated with a shorter …
Elacestrant Plus CDK4/6i May Optimize ESR1+ Breast Cancer …
2024年12月15日 · Although elacestrant (Orserdu) is approved for patients with ESR1 –posiitve breast cancer, elacestrant may optimize outcomes when combined with CDK4/6 inhibition in …
Arvinas and Pfizer Announce Positive Phase 3 VERITAC-2 Trial
3 天之前 · Potential Positives. VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful …
Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– …
3 天之前 · Of note, the PFS benefit associated with the investigational oral PROteolysis targeting chimera (PROTAC) ER degrader was observed only in patients harboring ESR1 mutations, …
- 某些结果已被删除